💊 Moderna Falls Despite RSV Vaccine Approval, Gilead Drops on Downgrade, Amgen Rises on Positive Trial Results | Biotech Sector Insights
(IBB) has seen a price increase of 0.3% since Thursday. Significant contributors to this performance include Vertex Pharmaceuticals (VRTX), which reached an all-time high and experienced substantial gains over the past year.
Welcome to the MarketReader Minute.
Below are AI-generated insights on moves in the health care/biotechnology sector, powered by MarketReader technology.
Friday, November 8
IBB [+0.3%]
iShares Biotechnology ETF
The iShares Biotechnology ETF (IBB) has seen a price increase of 0.3% since Thursday. Significant contributors to this performance include Vertex Pharmaceuticals (VRTX), which reached an all-time high and experienced substantial gains over the past year. Amgen Inc. (AMGN) also performed well, buoyed by positive trial results, while BioNTech SE (BNTX) received a "buy" upgrade from Goldman Sachs with an elevated price target. Fortrea Holdings Inc. (FTRE) reported notable revenue for Q3 despite a net loss. Additionally, IQV contributed positively to the ETF's overall performance.